SHANGHAI, China, Dec. 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that Governor Deval L. Patrick of the Commonwealth of Massachusetts, accompanied by other members of Massachusetts China Partnership Official Delegation, paid a visit to the company on December 7 in Shanghai, China.
Massachusetts China Partnership Official Delegation visitors included representatives from Massachusetts life science industry and academia such as Joshua Schafer Boger, Chief Executive Officer of Vertex Pharmaceuticals, and Jack Martin Wilson, President of University of Massachusetts.
Massachusetts is the U.S.'s epicenter for biotechnology, with over 300 biopharmaceutical companies located in the state. With the intellectual resources of leading universities and healthcare institutions, biotechnology has become one of the most important industries in Massachusetts.
During the meeting between the honorable guests and the management team of the company, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, gave Governor Patrick a brief introduction of the company and hoped for more collaboration opportunities between the two parties for continued expansion of the biopharmaceutical industry.
"I am here to encourage the collaboration that WuXi PharmaTech has with Massachusetts companies such as Vertex, and with enterprises everywhere that have the interest and ability to contribute to the future of healing," commented Governor Patrick in his address. "This collaboration has benefits for both Massachusetts and China, and for the future of health care all over the world. Working together, we will be stronger and more successful than we ever could be working apart."
The Governor added, "As in the United States, China's population is aging and life science is helping to alleviate suffering and improve quality of life for so many. By helping to find new treatments and cures while lowering health care system cost, life science gives us the opportunity to do well while doing good."
Commenting on the delegation's visit, Joshua Boger, Vertex Pharmaceuticals CEO and official delegation member said, "Through our over four years of cooperation, WuXi PharmaTech has become a trusted and important partner for our business. A trip to WuXi PharmaTech is a must-do for any life sciences company visiting China."
As China's leading provider of pharmaceutical R&D outsourcing services, WuXi PharmaTech helps more than 20 Massachusetts pharmaceutical and biotech companies accelerate their drug discovery from idea to market.
"We are much honored to host Governor Patrick and his delegation. WuXi PharmaTech has cultivated deep relationships with the financial and life science industries in Massachusetts. With the trust from our customers and support from the government, we look forward to serving more pharma and biotech companies in Massachusetts," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
About WuXi PharmaTech
Founded in 2000, Shanghai-based WuXi PharmaTech is the leading
China-based pharmaceutical and biotechnology R&D outsourcing company. As a
research- driven and customer-focused company, WuXi PharmaTech provides
pharmaceutical and biotechnology companies with a broad and integrated
portfolio of laboratory and research manufacturing services throughout the
drug discovery and development process. WuXi PharmaTech's services are
designed to assist its global partners in shortening the cycle and lowering
the cost of drug discovery and development by providing cost-effective and
efficient outsourcing solutions that save its customers both time and
money. Its operations are grouped into two segments: laboratory services,
consisting of discovery chemistry, service biology, analytical, toxicology,
pharmaceutical development and process development services; and
manufacturing, focusing on manufacturing of advanced intermediates and
active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech
provided services to over 80 pharmaceutical and biotechnology customers,
including nine of the top ten pharmaceutical companies in the world, as
measured by 2006 total revenues. For more information, please visit
For more information, please contact:
|SOURCE WuXi PharmaTech|
Copyright©2007 PR Newswire.
All rights reserved